The allergic effector unit: From basic science to drug-targetable mast cell–eosinophil interactions in patients

Pier Giorgio Puzzovio, Francesca Levi-Schaffer*

*Corresponding author for this work

Research output: Contribution to journalLetterpeer-review

3 Scopus citations
Original languageAmerican English
Pages (from-to)3845-3846
Number of pages2
JournalJournal of Allergy and Clinical Immunology: In Practice
Volume9
Issue number10
DOIs
StatePublished - Oct 2021

Bibliographical note

Funding Information:
This study was funded by Rosetrees Trust (UK), Aimwell Charitable Trust (UK), Israel Science Foundation (Grant no. 442/18), Israel Ministry of Science & Technology, and Emalie Gutterman Memorial Endowed Fund for COPD Related Research (USA). F. Levi-Schaffer is affiliated with the Adolph and Klara Brettler Center for Molecular Pharmacology and Therapeutics at the School of Pharmacy of the Hebrew University of Jerusalem.

Funding Information:
This study was funded by Rosetrees Trust (UK), Aimwell Charitable Trust (UK), Israel Science Foundation (Grant no. 442/18), Israel Ministry of Science & Technology, and Emalie Gutterman Memorial Endowed Fund for COPD Related Research (USA). F. Levi-Schaffer is affiliated with the Adolph and Klara Brettler Center for Molecular Pharmacology and Therapeutics at the School of Pharmacy of the Hebrew University of Jerusalem.

Cite this